Alarmins are structurally diverse endogenous mediators that can induce both recruitment and activation of APCs, such as DCs and monocytes/macrophages Bianchi, 2007; Yang et al., 2009) . Alarm ins are predominantly produced in peripheral tissues by infiltrating leukocytes or epithe lial cells in response to tissue damage and microbial attack. All alarmins identified so far, such as defensins, cathelicidins, eosinophil derived neurotoxin, granulysin, and HMGB1 (highmobility group box 1) protein, have been shown to enhance inflammation, anti microbial defense, adaptive immunity, and wound healing (Wang et al., 1999; RovereQuerini et al., 2004; Kurosaka et al., 2005; Bianchi, 2007; Straino et al., 2008; Yang et al., 2008 Yang et al., , 2009 Chen et al., 2009; Tewary et al., 2010) . However, it remains to be shown that any alar min is crucial for the induction of antigen specific immune response.
HMGB1 and HMGN1 (highmobility group nucleosomebinding protein 1) are members of the HMG superfamily of nonhistone chromatin binding proteins (Bianchi and Agresti, 2005) . HMG superfamily proteins are classified into (sham) or presence of recombinant HMGN1 or HMGN2 (both at a final concentration of 1 µg/ml) for 48 h before they were immunostained and analyzed by flow cytometry for the expression of the indicated surface molecules (open area, isotype-matched control). Shown are the results of one experiment representative of five. (B) Human MoDCs were incubated at 5 × 10 5 /ml in the absence (sham) or presence of recombinant HMGN1 or HMGN2 at the indicated doses for 24 h (left) or at 1 µg/ml for the indicated times (right), and cytokine levels in the culture supernatants were quantitated by cytokine array (mean ± SD; n = 3). (C) Human MoDCs cultured at 1 × 10 6 /ml in the absence (sham) or presence of 1 µg/ml of recombinant HMGN1 for 24 h were suspended in chemotaxis medium, and their migration in response to 100 ng/ml CCL5, CCL21, or CXCL12 was measured by chemotaxis assay. The migration of DCs was enumerated by the mean (±SD) of six high-power fields (HPF) randomly chosen from triplicate wells. Shown are the results of one experiment representative
RESULTS

HMGN1 promotes DC maturation
To determine whether members of the HMGN subfamily have any alarmin activities, we first investigated whether recombinant human HMGN1 or HMGN2 could induce DC maturation. DC maturation has three phenotypic hallmarks including upregulation of certain surface marker expression, induction of proinflammatory cytokines, and acquisition of functional CCR7 (Banchereau and Steinman, 1998) . Human monocytederived DCs (MoDCs) incubated with 1 µg/ml of recombinant HMGN1 for 48 h upregulated the expression of costimulatory (CD80 and CD86), MHC (class I and II), and CD83 (a marker of DC maturation) molecules (Fig. 1 A) . HMGN1 stimulated DC production of a variety of pro inflammatory cytokines (IL6, IL8, TNF, and IL12p70) in a dose and timedependent manner (Fig. 1 B) . Additionally, DCs incubated with HMGN1 for 24 h downregulated their capacity to migrate to CCL5 and upregulated their capacity to migrate to CCL21, a ligand for CCR7 (Fig. 1 C) . In con trast, DCs similarly treated with recombinant HMGN2 did not upregulate surface costimulatory/MHC molecules ( Fig. 1 A) or produce any of the tested cytokines ( Fig. 1 B) , nor did they become responsive to CCL21 (not depicted). Therefore, HMGN1 but not HMGN2 exhibited the capac ity to induce phenotypic maturation of human MoDCs.
To determine whether HMGN1induced maturation of DCs was reflected at the functional level, HMGN1treated DCs were analyzed for their capacity to stimulate the prolif eration of allogeneic T lymphocytes in a mixed lymphocyte reaction using sham and LPStreated DCs as negative and positive controls, respectively (Fig. 1 D) . Shamtreated DCs did not stimulate [ 3 H]TdR incorporation by allogeneic T cells. However, DCs treated with HMGN1 stimulated [ 3 H]TdR incorporation by allogeneic T cells when used at a DC/T ratio higher than 1:1,250, indicating that HMGN1 treated DCs exhibited remarkably enhanced capacity to pres ent antigen to T cells for their activation. Thus, HMGN1 is capable of inducing both phenotypic (Fig. 1 , A-C) and func tional ( Fig. 1 D) maturation of DCs.
HMGN1 is composed of two major domains, an Nterminal nucleosomal binding domain (NBD) and a Cterminal chromatinunfolding domain (Hock et al., 2007) . To deter mine which domain plays a more important role in its DC activating effect, we synthesized two peptides that correspond to the Nterminal (N1ND = HMGN1 ) and Cterminal three (HMGA, HMGB, and HMGN) subfamilies, each of which contains several members, such as HMGB1-3, HMGN1-4, etc. (Hock et al., 2007) . The expression of HMG proteins is developmentally regulated. In adults, HMGB1 is highly expressed in all cell types, whereas other HMG proteins are more selectively expressed (Hock et al., 2007) . For example, HMGN1 is highly expressed in proliferative tissues that undergo constant turnover, such as stem cells and some epithelial cells (Mohamed et al., 2001; Bianchi and Agresti, 2005; Furusawa et al., 2006; Hock et al., 2007) . Intranuclear HMGs are major regulators of chromosome architecture and gene transcription (Calogero et al., 1999; Birger et al., 2003; Bianchi and Agresti, 2005; Hock et al., 2007) . Over the past decade, HMGB1 has been shown to have multiple extracellular activities such as me diating diverse inflammatory reactions (Wang et al., 1999 (Wang et al., , 2004 Tian et al., 2007; Chen et al., 2009) , induction of activation and migration of many cell types (Wang et al., 1999; Messmer et al., 2004; RovereQuerini et al., 2004; Yang et al., 2007) , promo tion of wound healing (Straino et al., 2008) , and acting as an alarmin (Wang et al., 1999; Messmer et al., 2004; Rovere Querini et al., 2004; Bianchi, 2007; Yang et al., 2007 Yang et al., , 2009 Urbonaviciute et al., 2008; Chen et al., 2009) . However, it is unknown whether members of the HMGN subfamily have any extracellular alarmin activities.
In this study, we demonstrate that HMGN1 has extra cellular alarmin activity and plays an important role in LPS induced innate and adaptive immune responses. HMGN1 induces phenotypic and functional maturation of DCs in a TLR4 (Tolllike receptor 4), MyD88 (myeloid differentia tion primary response gene 88), and TRIF (TIR domaincontaining adaptor protein inducing IFN)dependent manner. The contribution of HMGN1 to immunity was demonstrated by two complementary approaches: (1) exoge nous HMGN1 enhanced antigenspecific immune responses upon administration with the antigen, and (2) HMGN1 / mice manifested greatly reduced antigenspecific humoral and cellular immune responses in comparison with litter matematched HMGN1 +/+ mice. The reduction in immune re sponses in HMGN1 / mice in comparison with HMGN1 +/+ mice was accompanied by greatly decreased recruitment of leukocytes including APCs and reduced production of pro inflammatory cytokines in the serum of immunized mice. Therefore, HMGN1 acts as an alarmin and plays a critical role in LPSinduced development of innate and adaptive immune responses.
of two. (D) Human MoDCs cultured in the absence or presence of 1 µg/ml HMGN1 or LPS for 48 h were irradiated at 3,000 rad and incubated in triplicate with allogeneic human peripheral blood T cells (10 5 /well) in 0.2 ml of medium in wells of 96-well flat-bottomed plates at the indicated DC/T ratios for 5 d. The proliferation was measured as the mean (±SD) [ 3 H]TdR incorporation of triplicate wells. Shown are the results of one experiment representative of three. (E and F) Human MoDCs were incubated at 1 × 10 6 /ml in the absence (sham) or presence of synthetic HMGN1 N-terminal domain (N1ND, HMGN1 1-52 ) or C-terminal domain (N1CD, HMGN1 53-100 ) at 10 µg/ml for 48 h before measurement of DC surface marker expression by flow cytometry (E, gray area: sham-treated DCs) and cytokine production in the supernatants (F; mean ± SD; n = 3). (G) Human DCs were incubated at 5 × 10 5 /ml in medium in the absence (sham) or presence of 1 mg/ml HMGN1 or mutated HMGN1 for 24 h before obtaining supernatants for measurement of the indicated cytokines. Shown is the mean (±SD) of triplicate wells of one experiment representative of two. *, P < 0.05 by Student's t test when compared with the sham treatment.
Among the many diverse DCactivating stimulants, only the IL1 family of cytokines (including IL18) and many TLR ligands activate DCs in a MyD88dependent manner (Kaisho and Akira, 2001; Akira and Takeda, 2004) . There is no obvious structural or functional resemblance between HMGN1 and cytokines. We therefore investigated whether HMGN1 uses any of the TLRs as its receptor. Screening HEK293 cells transfected to express various TLR revealed that HMGN1 could induce the production of IL8 and TNF in HEK293 cells transfected with a combination of human TLR4, MD2, and CD14 but not in untransfected HEK293 cells (Fig. S2) . Additionally, HMGN1 stimulated the produc tion of TNF, IL6, IL10, IL12p70, and CCL5 in DCs derived from HeN mice but not in DCs from HeJ mice that harbor a lossoffunction TLR4 mutation (Fig. 3 D) . These data indicate that HMGN1 is an endogenous mediator that induces DC activation in a TLR4dependent manner.
To determine whether HMGN1 could interact with TLR4, HMGN1 was incubated with the TLR4-MD2 com plex and subsequently analyzed by coimmunoprecipitation. Rabbit antiHMGN1 coimmunoprecipitated both TLR4 and MD2 ( Fig. 3 E, top) , whereas mouse antiMD2 coimmuno precipitated HMGN1 (Fig. 3 E, bottom) , suggesting an associ ation of HMGN1 with the TLR4-MD2 complex. To better define the possible site of interaction between HMGN1 and MD2 and/or TLR4, effects of HMGN1 on binding of en dotoxin (i.e., tritiated meningococcal lipooligosaccharide [[ 3 H]LOS]) to preformed FLAG-TLR4 ECD -MD2 complex or on binding of [ 3 H]LOS-MD2 to TLR4 ECD were measured using assays previously described (Teghanemt et al., 2008;  (N1CD = HMGN1 53-100 ) half of HMGN1 and investigated the effect of the two peptides on DC maturation. N1ND containing the NBD of HMGN1 upregulated the expres sion by DCs of surface markers (Fig. 1 E) and their produc tion of IL12p70 and TNF (Fig. 1 F) , whereas N1CD containing the chromatinunfolding domain of HMGN1 failed to do so when tested at identical concentrations (Fig. 1 , E and F), suggesting that the NBD accounts for the DC activating effect of HMGN1.
Because HMGN1 is a nucleosomal binding protein that regulates the structure of chromatin and gene transcrip tion (Bianchi and Agresti, 2005; Hock et al., 2007) , the DCactivating activity of HMGN1 could be caused by its chromatinbinding activity. To rule out this possibility, we compared the cytokineinducing capacity of native HMGN1 with that of HMGN1[S20, 24E], a mutated HMGN1 that does not bind to nucleosomes (PrymakowskaBosak et al., 2001) . Interestingly, both the native and mutant HMGN1 proteins induced similar upregulation of CD83, CD80, CD86, HLAABC, and HLADR on the surface of DCs (Fig. S1 ) and the production of comparable levels of various cytokines by DCs (Fig. 1 G) , indicating that the capacity of HMGN1 to induce DC activation is independent of its chromatinbinding capability.
HMGN1 induces the recruitment of DCs
Another feature of alarmins is their capacity to recruit APCs Yang et al., 2009) . HMGN1 injected into the peritoneal cavity of C57BL/6 mice by 4 h increased the total number of leukocytes infiltrating the peri toneal cavity in a dosedependent manner (Fig. 2 A) . The leukocyte subsets present in the peritoneal cavity of mice 4 h after i.p. injection of HMGN1 (1 µg/mouse) were analyzed by flow cytometry. HMGN1 caused a two to fivefold in crease in various types of mouse DCs, including myeloid (CD11c + /CD11b + ) and plasmacytoid (CD11c + /B220 + ) DCs (Fig. 2 B) . Therefore, in addition to activating DCs, HMGN1 can also recruit DCs in vivo, indicating that extracellular HMGN1 has the characteristics of an alarmin.
HMGN1 activates a signal transduction pathway that relies on MyD88 and TLR4
The capacity of HMGN1 to initiate signal transduction in DCs was investigated using DCs generated from mouse bone marrow progenitors. HMGN1 dosedependently stimulated the production of various cytokines and che mokines by mouse DCs (Fig. 3 A) . HMGN1 treatment resulted in a decrease in IB and increase in the phos phorylated forms of p44/42, p38, and JNK in DCs in a timedependent manner, suggesting that HMGN1 activated DC NFB and multiple mitogenactivated protein kinases (MAPKs) in DCs (Fig. 3 B) . Interestingly, HMGN1stimulated production of TNF, IL1, and IL6 was markedly reduced in MyD88 / DCs in comparison with MyD88 +/+ DCs, indicating that HMGN1 induction of DC activation is MyD88 dependent (Fig. 3 C) . (A) 8-wk-old female C57BL/6 mice (five mice/group) were injected i.p. with PBS alone or PBS containing the indicated amount of HMGN1. After 4 h, leukocytes in the peritoneal cavity were enumerated. Shown is the mean (±SD) number of leukocytes. *, P < 0.05 by ANOVA when compared with mice injected with PBS alone. Shown are the results of one experiment representative of three. (B) Two groups of female C57BL/6 mice (10 wk old; n = 5) were injected i.p. with PBS alone or PBS containing 1 µg HMGN1. After 4 h, leukocytes were harvested from the peritoneum and immunostained with either isotype-matched control antibodies or a combination of PE-conjugated anti-mouse CD11c, FITC-conjugated anti-mouse CD11b, and APC-conjugated anti-mouse B220. The indicated subpopulations of DCs were determined by flow cytometry and calculated as fold increase induced by HMGN1 over the PBS group. Shown are the results of one experiment representative of two.
However, when the same concentrations of TLR4 ECD ± [ 3 H]LOS-MD2 were incubated in the absence or presence of HMGN1 and the reaction mixture was analyzed by Sephacryl HR S300 chromatography, incubation with HMGN1 resulted in an earlier elution of the recovered [ 3 H]LOScontaining species. In the absence of HMGN1, there were two peaks of Piazza et al., 2011) . Whereas transfer of [ 3 H]LOS from a monomeric complex of [ 3 H]LOS-sCD14 to FLAG-TLR 4 ECD -MD2, as measured by cocapture of [ 3 H]LOS by anti FLAG agarose, was nearly completely inhibited by the addition of an 200fold molar excess of unlabeled LOS, a similar molar excess of HMGN1 had little or no effect (Fig. 3 F) . . HMGN1 activation of DCs is dependent on TLR4 and MyD88. (A) DCs generated from bone marrow progenitors of C57BL/6 mice were incubated at 5 × 10 5 /ml in medium containing the indicated concentration of HMGN1 for 48 h, and cytokines in the supernatant were measured by cytokine array. Shown is the mean (±SD) of triplicate wells of one experiment representative of three. *, P < 0.05 by Student's t test when compared with DCs cultured without HMGN1. (B) Mouse bone marrow-derived DCs were treated with 1 µg/ml HMGN1 for 20 or 60 min before they were solubilized in lysis buffer (10 6 DCs/0.1 ml), and the levels of I-B and phosphorylated MAPKs (p44/42, p38, and JNK) in DC lysates were detected by Western blot. After stripping, the membranes were reprobed with GAPDH and the unphosphorylated MAPKs antibodies. The results of one experiment representative of two are shown. (C) Bone marrow-derived DCs from MyD88 +/+ and MyD88 / mice were cultured at 5 × 10 5 /ml without or with 1 µg/ml HMGN1 for 48 h, and cytokines were measured by cytokine array. Shown is the mean (±SD) of three independent experiments. *, P < 0.05 by ANOVA. (D) BMderived DCs from C3HeN and C3HeJ mice were cultured at 5 × 10 5 /ml without or with 1 µg/ml HMGN1 for 48 h, and cytokines were measured by cytokine array. Shown is the mean (±SD) of three independent experiments. *, P < 0.05 by ANOVA. apparent M r 190,000 (earlier elution peak) and 25,000 (later peak) corresponding to [ 3 H]LOS-MD2-TLR4 ECD and [ 3 H]LOS-MD2, respectively (Fig. 3 G) . In contrast, the reac tion mixture in the presence of HMGN1 gave rise to two peaks of 210,000 and 40,000, respectively ( Fig. 1 G) . Together with the coimmunoprecipitation data, these findings strongly suggest that HMGN1 (M r = 15,000) forms part of a complex with [ 3 H]LOS-MD2-TLR4 ECD and [ 3 H]LOS-MD2, most consistent with binding of HMGN1 to a site in MD2 distinct from where either endotoxin or TLR4 interacts.
HMGN1 induces DC activation in a TRIF-dependent manner
HMGN1induced activation of DCs was dependent on TLR4, raising concern that the recombinant HMGN1 might be contaminated with endotoxin. However, the ability of unlabeled LOS but not HMGN1 at similar molar excess to compete with [ 3 H]LOS-sCD14 for binding to the FLAG-TLR4 ECD -MD2 complex ( Fig. 3 F) indicated no gross con tamination of recombinant HMGN1 with endotoxin. Recombinant HMGN1 displayed a single band of expected size on SDSPAGE gel ( Fig. S3 ) and was negative for endo toxin when tested by a limulus amebocyte lysate assay (not depicted). The capacity of recombinant HMGN1 to induce production by DCs of IL6 and TNF was destroyed by boil ing for 5 min but was not affected when digested with DNase I for 30 min before addition to DC culture ( Fig. S4 ), suggest ing that the DCactivating effect of HMGN1 preparation was neither caused by endotoxin or bacterial DNA contami nation. To further exclude the possibility of endotoxin con tamination, we expressed HMGN1 in insect cells, purified recombinant HMGN1 from the supernatant of insect culture (designated riN1) using affinity chromatography under sterile conditions, and investigated whether riN1 could still activate DCs. As shown in Fig. 4 , riN1 enhanced DC expression of CD80, CD86, and HLADR (Fig. 4 A) and DC production of IL6, IL12p70, and TNF (Fig. 4 B) . Moreover, riN1 in duced remarkable upregulation of CD83, CD80, CD86, and IA/E in HeN DCs, but to a much lesser extent in HeJ DCs (Fig. 4 C) . Furthermore, riN1induced DC pro duction of IL6, IL10, IL12p70, and TNF was significantly reduced in the absence of functional TLR4 (Fig. 4 D) . Thus, riN1induced DC maturation is also dependent on TLR4. (C) Flow cytometric analysis of the expression of DC surface molecules after treatment without or with 1 µg/ml LPS or 10 µg/ml riN1 for 48 h. Shown are the overlay histograms of C3H/HeN or C3H/HeJ DCs of one experiment representative of two (gray histograms indicate sham-treated DCs). (D) C3HeN and C3HeJ mouse DCs were cultured at 5 × 10 5 /ml in the absence or presence of 5 µg/ml riN1 for 48 h, and cytokines were measured in the supernatants. (E) Cytokine production by MyD88 +/+ or MyD88 / DCs (5 × 10 5 /ml) after 48-h treatment with or without riN1. (F) DCs from TRIF +/+ or TRIF / mice were incubated at 10 6 /ml without or with 5 µg/ml riN1 for 48 h, and cytokines in the supernatants were measured. (D-F) Shown is the mean (±SD) of two (E and F) or three (D) independent experiments. *, P < 0.05 by ANOVA.
HMGN1 polarizes OVAspecific Th1 response (Fig. 5 B) . To determine whether HMGN1 could also enhance the immune response to a physiologically relevant antigen, A/J mice were immunized i.p. with anthrax vaccine adsorbed (AVA), the human anthrax vaccine licensed in the US, to gether with HMGN1. HMGN1 dosedependently enhanced the production of primary and secondary IgG specific for the protective antigen (PA) of anthrax toxin, demonstrating that HMGN1 can enhance immune response against a physiologi cally relevant antigen (Fig. 5 C) . These results demonstrate that exogenous HMGN1 can act as an adjuvant to enhance antigenspecific humoral and cellular immune responses.
The ability of the synthetic Nterminal portion of HMGN1 (less likely to be contaminated with endotoxin) to activate DCs (Fig. 1 , E and F) is also consistent with the view that HMGN1 by itself possesses the capacity to activate DCs in a TLR4dependent manner.
To confirm whether riN1induced DC activation was also dependent on MyD88, MyD88 +/+ and MyD88 / mouse DCs were treated with riN1, and their production of TNF, IL1, and IL6 was compared. Under identical conditions, riN1 promoted the production of TNF, IL1, and IL6 by MyD88 +/+ DCs but not by MyD88 / DCs (Fig. 4 E) . There fore, riN1induced DC activation was also dependent on the presence of MyD88.
To determine whether HMGN1induced DC activation also involves TRIF, DCs generated from TRIF +/+ and TRIF / mouse bone marrow progenitors were treated with riN1 for the induction of mediators that rely on TRIF. TRIF +/+ DCs produced IL12p40, IP10, and CCL5 in re sponse to riN1; however, TRIF / DCs treated under iden tical conditions produced much less IL12p40, IP10, and CCL5, indicating that activation of DCs by HMGN1 was TRIF dependent (Fig. 4 E) . Comparison of LPS and riN1 induced phenotypic maturation of HeN and HeJ DCs re vealed some differences. Although LPSinduced phenotypic maturation relied on TLR4, riN1induced phenotypic changes were not completely TLR4 dependent (Fig. 4 C) . Further more, HMGN1 stimulation of certain DC inflammatory cyto kines and chemokines (e.g., TNF, IL1, IL6, IL12, and IP10) was not completely dependent on MyD88, TLR4, or TRIF (Fig. 3 , C and D; and Fig. 4 D) . Therefore, HMGN1 may use an additional pathway for DC activation in addition to the major TLR4-MyD88-TRIF pathway.
HMGN1 is critical for the induction of antigen-specific immune responses DC activation and recruitment are essential for the induction of adaptive immunity (Banchereau and Steinman, 1998; Iwasaki and Medzhitov, 2004) . To investigate the potential contribu tion of HMGN1 to the induction of immunity, C57BL/6 mice were immunized i.p. with OVA alone or together with HMGN1 or alum (as a positive control) on day 1 and boosted with OVA on day 14. On day 21, the splenocytes of immu nized mice were stimulated with various doses of OVA to determine OVAspecific proliferation and cytokine produc tion, two parameters indicative of the development of OVA specific cellular immune response. In comparison with mice immunized with OVA alone (PBS group), the splenocytes of mice immunized with OVA plus HMGN1 not only prolifer ated ex vivo more robustly in response to OVA (Fig. 5 A) but also produced more IFN and TNF (Fig. 5 B) , demon strating that HMGN1 enhanced an OVAspecific cellular immune response. Alum, as expected, also enhanced the OVAspecific cellular immune response (Fig. 5, A and B) but promoted splenocyte production of IL4, IL10, and TNF. In contrast, HMGN1 promoted splenocyte production of IFN and TNF but not IL4, indicating that exogenous 8-wk-old female C57BL/6 mice were immunized i.p. with OVA (50 µg/ mouse), OVA + alum (3 mg/mouse), or OVA + HMGN1 (1 µg/mouse) on day 1 and boosted i.p. with OVA on day 14. On day 21, the spleens of immunized mice were removed, and single-cell suspension was evaluated for OVA-specific cellular immune responses. (A) Splenocytes were cultured in triplicate in a 96-well plate (5 × 10 5 /0.2 ml/well) in the presence of specified concentrations of OVA for 4 d. The culture was pulsed with 1 µCi/well [ 3 H]TdR for the last 18 h before harvest for measurement of [ 3 H]TdR incorporation. OVA-specific proliferation of splenocytes is shown as the mean cpm (±SD) of each group (n = 4). (B) Splenocytes were cultured in duplicate in a 48-well plate (2.5 × 10 6 /0.5 ml/well) in the presence of 100 µg/ml OVA for 48 h, and cytokines in the supernatants were quantitated. Shown is the mean cytokine concentration (±SD) of each group (n = 4) of one experiment representative of three. *, P < 0.05 by ANOVA when compared with the PBS group. (C) A/J mice (n = 4, 10 wk old, female) were immunized i.p. with AVA (the licensed human anthrax vaccine in the US) in the absence or presence of HMGN1 at specified doses (1 or 5 µg/mouse) on day 1 and booster immunized i.p. on day 14. Sera were collected on day 10 and 20 for the measurement of primary and secondary antibody responses, respectively. The IgG specific for the PA of anthrax in the serum was quantitated by anti-PA ELISA. Shown is the geometric mean anti-PA titer (±SD) of each group of one representative experiment out of three. *, P < 0.05 by ANOVA when compared with the AVA alone group. responses (Fig. 6 A) , enhanced OVAspecific proliferation of splenocytes (Fig. 6 B) , and increased OVAspecific spleno cyte production of various cytokines (Fig. 6 C) . In contrast, Hmgn1 / mice produced lower levels of primary and sec ondary antiOVA antibodies than Hmgn1 +/+ mice (Fig. 6 A) . In addition, the splenocytes of Hmgn1 / mice immu nized with OVA in the presence of LPS showed less OVA specific proliferation than splenocytes of similarly immunized Hmgn1 +/+ mice (Fig. 6 B) . The reduction in OVAspecific proliferation of splenocytes of immunized Hmgn1 / mice was not caused by an intrinsic deficiency in the capacity of To further investigate the contribution of HMGN1 to adaptive immunity, we examined the effect of HMGN1 KO on in vivo induction of antigenspecific immune responses. Hmgn1 / and littermatematched Hmgn1 +/+ mice were immunized i.p. with OVA alone or in the presence of an ad juvant, LPS. Immunization with OVA alone did not result in the generation of any immune response in Hmgn1 / or Hmgn1 +/+ mice (Fig. 6) . Hmgn1 +/+ mice immunized with OVA in the presence of LPS mounted OVAspecific hu moral and cellular immune responses as indicated by elevated production of primary and secondary antiOVA IgG antibody The results of one experiment representative of three are shown as the mean cpm (±SD) of triplicate wells. *, P < 0.05 by Student's t test. (C) OVA-specific cytokine production by splenocytes of immunized Hmgn1 +/+ and Hmgn1 / mice. Splenocytes were cultured in a 48-well plate (2.5 × 10 6 /0.5 ml/well) in the presence of 100 µg/ml OVA for 48 h before the measurement of cytokines in the supernatants. Shown is the mean concentration (±SD) of cytokines (n = 3). *, P < 0.05 by ANOVA. (D and E) Male Hmgn1 / and littermate-matched Hmgn1 +/+ mice (n = 4) were immunized i.p. with OVA (50 µg/mouse) or radiation-inactivated OVA-expressing E. coli (10 6 /mouse) on day 1 and boosted i.p. on day 14. Splenocytes pooled from the five mice were cultured in triplicate in wells of a 96-well plate (5 × 10 5 /0.2 ml/well) in the presence of specified concentrations of OVA for 4 d. The cultures were pulsed with 1 µCi/well [ 3 H]TdR for the last 18 h before harvest for measurement of [ 3 H]TdR incorporation. The results are shown as the mean cpm (±SD) of triplicate wells. *, P < 0.05 by Student's t test. Alternatively, splenocytes were cultured in a 48-well plate (2.5 × 10 6 /0.5 ml/well) in the presence of 100 µg/ml of OVA for 48 h before the measurement of cytokines in the supernatants. Shown is the mean concentration (±SD) of cytokines (n = 5) of one experiment representative of two. *, P < 0.05 by ANOVA.
intrinsically deficient in antigen uptake or presentation (Fig. S7,  A and B) . Hmgn1 / DCs did not show any defect in vitro in LPSinduced activation of NFB and multiple MAPKs (Fig. S7 C) or LPSinduced production of a variety of cyto kines and chemokines measured (Fig. S7 D) . We therefore investigated whether immunized Hmgn1 / mice were de ficient in APC activation and recruitment. Immunization with OVA i.p. in the presence of LPS induced elevated serum levels of IL1, IL2, IL6, IL12p70, and TNF at 24 and 96 h after immunization in Hmgn1 +/+ but not in litter matematched Hmgn1 / mice (Fig. 7 A) . This deficient cytokine production is presumably indicative of reduced in vivo activation of APCs in immunized Hmgn1 / mice. Additionally, i.p. administration of OVA plus LPS resulted in a greater accumulation of total leukocytes as well as CD11c + / IA/E + cells than injecting with OVA alone in Hmgn1 +/+ but not in littermatematched Hmgn1 / mice, indicating that HMGN1 deletion caused defective recruitment of APCs (Fig. 7 B) . Thus, defective APC activation and recruitment presumably contributed to the reduction of antigenspecific immune responses in Hmgn1 / mice.
The decrease in APC activation and/or recruitment in immunized Hmgn1 / mice might result from a deficiency in the production of extracellular HMGN1. To determine whether HMGN1 was produced upon immunization, the peritoneal lavages of immunized C57BL/6 mice were tested for the presence of HMGN1 protein by Western blot. The la vage supernatants collected 4 and 22 h after immunization with OVA in the presence of LPS contained HMGN1 pro tein, whereas the supernatants of mice immunized with OVA alone did not, indicating that HMGN1 was produced extra cellularly upon immunization in the presence of LPS (Fig. 7 C) . HMGN1 was not detected in the lysate of peritoneal cell pel lets (not depicted), suggesting that either peritoneal leuko cytes completely released their HMGN1 or cells other than leukocytes were responsible for the local production extra cellular HMGN1.
To determine whether leukocyte or nonleukocyte derived HMGN1 played a more important role in the induction of immune response, we immunized WT→KO (lethally irradiated Hmgn1 / mice reconstituted with Hmgn1 +/+ bone marrow) and KO→WT (lethally irradiated Hmgn1 +/+ mice reconstituted with Hmgn1 / bone mar row) bone marrow chimeric mice and evaluated their OVA specific immune responses. In comparison with KO→WT chimeric mice, WT→KO chimeric mice produced much less serum antiOVA IgG antibodies upon i.p. immunization with OVA plus LPS (Fig. 7 D) . Additionally, the splenocytes of immunized WT→KO chimeric mice, when stimulated with OVA, not only proliferated less robustly (Fig. S8 ) but also secreted much less IL4, IL5, IL13, IL17, and IFN (Fig. 7 E) than the splenocytes of similarly immunized KO→ WT chimeric mice. Thus, production of HMGN1 at the site of immunization, which was mostly derived from nonleu kocytes, is critical for the induction of antigenspecific im mune responses.
Hmgn1 / splenocytes to mount a proliferative response be cause splenocytes of immunized Hmgn1 / and Hmgn1 +/+ mice proliferated similarly to polyclonal stimulators including antiCD3, IL2, Con A, and PHA (Fig. S5) . Furthermore, the splenocytes of Hmgn1 / mice immunized with OVA in the presence of LPS produced lower levels of IL4, IL5, IL13, IL17, and IFN than splenocytes of similarly immunized Hmgn1 +/+ mice (Fig. 6 C) . These results further demonstrate the critical role of HMGN1 in the induction of antigen specific humoral and cellular immune responses.
To determine whether HMGN1 contributes to the de velopment of immune response in a more physiologically relevant manner, we immunized mice with radiation inactivated OVAexpressing Escherichia coli (EC OVA ) and evaluated whether HMGN1 was required for the generation of antigenspecific T cell response. Splenocytes of Hmgn1 +/+ mice immunized with EC OVA proliferated in response to in vitro OVA restimulation in a dosedependent manner (Fig. 6 D) and increased production of OVAspecific T cell cytokines including IL4, IL5, IL17, and predominantly IFN (Fig. 6 E) , suggesting that immunization with EC OVA in duced the development of a robust Th1polarized antiOVA immune response. In contrast, Hmgn1 / mice similarly immunized with EC OVA exhibited greatly reduced OVA specific splenocyte proliferation and production of IL4, IL5, IL17, and IFN (Fig. 6, D and E) . Hmgn1 +/+ and Hmgn1 / mice immunized with OVA alone, as antici pated, did not manifest a detectable level of immune re sponse (Fig. 6, D and E) . Thus, HMGN1 is critical for the development of antigenspecific immune responses in a physiologically relevant setting.
Production of HMGN1 at the site of immunization is necessary for the induction of antigen-specific immune response
We next investigated why HMGN1 deficiency led to a reduction in antigenspecific immune responses. Although Hmgn1 / mice have a deficiency in DNA repair processes and the differentiation of corneal epithelial cells (Birger et al., 2003 , Hmgn1 / and littermatematched Hmgn1 +/+ mice had similar spleen size and structure (not depicted) and similar number and distribution of various subsets of leuko cytes (e.g., CD4 + T cells, CD8 + T cells, B cells, DC/mono cytes, and granulocytes) in peripheral blood, bone marrow, lymph nodes, and spleen (Fig. S6) , indicating that Hmgn1 / mice had no obvious abnormality in the development of the immune system. Reduction of antigenspecific immune response in Hmgn1 / mice was unlikely to be caused by malfunction of lymphocytes because Hmgn1 / spleen lympho cytes responded similarly to polyclonal stimulations (Fig. S5) . DCs derived from the bone marrow progenitors of Hmgn1 / and littermatematched Hmgn1 +/+ mice, when loaded with OVA and subsequently matured with a cytokine cocktail consisting of IL1, TNF, and soluble CD40 ligand, stimu lated comparable levels of OT I and OT II lymphocyte proliferation, indicating that Hmgn1 / DCs were not greatly reduced in Hmgn1 / mice; however, TG and MDP stimulated similar levels of leuko cyte infiltration and cytokine production in both Hmgn1 +/+ and Hmgn1 / mice (Fig. 8, A and B) . Therefore, Hmgn1 / mice have no generalized deficiency in the manifestation of innate response. Lack of endogenous HMGN1 compro mised LPSinduced innate/inflammatory response, which accounts at least in part for the reduction of antigenspecific immune response upon immunization with OVA and LPS in Hmgn1 / mice.
DISCUSSION
Alarmins are defined as endogenous mediators that are capa ble of rapidly inducing the activation and recruitment of APCs and consequently capable of promoting the induction
HMGN1 contributes to LPS-induced innate immune responses
Hmgn1 / mice showed markedly reduced leukocyte infil tration and production of inflammatory cytokines in re sponse to i.p. administration of OVA and LPS, suggesting that LPSinduced innate immune response was dependent on the presence of HMGN1 (Fig. 7, A and B) . To evaluate whether Hmgn1 / mice have a generalized deficiency in the manifestation of innate/inflammatory response, we in vestigated the capacity of thioglycolate (TG) and muramyl dipeptide (MDP) to induce peritoneal inflammatory re sponse in Hmgn1 / and littermatematched Hmgn1 +/+ mice. Injection i.p. of LPS, TG, or MDP resulted in peri toneal infiltration of leukocytes and production of IL6, JE, and KC in Hmgn1 +/+ mice (Fig. 8, A and B) . LPS induced leukocyte infiltration and cytokine production were Notably, Hmgn1 / mice did not manifest a complete deficiency in the development of LPSinduced innate and antigenspecific immune response. Upon i.p. immunization with OVA in the presence of LPS, Hmgn1 / mice showed a partial reduction in both antibody production (Fig. 6 A) and OVAspecific splenocyte proliferation (Fig. 6 B) . LPS induced infiltration of peritoneal leukocytes as well as perito neal production of IL6 and JE were not completely abrogated in Hmgn1 / mice (Fig. 8, A and B) . In addition, EC OVA induced antigenspecific immune response was dramatically reduced but not completely abrogated in Hmgn1 / mice in comparison with littermatematched Hmgn1 +/+ mice (Fig. 6 , D and E). It is possible that other alarmins such as HMGB1 may partially compensate for the deficiency of HMGN1. It is still remarkable that HMGN1 demonstrates a major nonre dundant role in the development of LPSinduced innate and antigenspecific immune responses.
HMGN1 used in some experiments of the present study was expressed using a prokaryotic expression system and pu rified from E. coli cultures, which raised the issue of potential endotoxin contamination, particularly because HMGN1 was found to activate DCs in a TLR4dependent manner. How ever, multiple lines of evidence indicate that HMGN1 is re sponsible for the DCactivating effect rather than endotoxin contamination. First of all, the HMGN1 preparation was quite pure (a single band under SDSPAGE) and contained undetectable level of endotoxin, and its DCactivating effect was destroyed by boiling. HMGN2 preparation expressed and purified in a similar manner as HMGN1 did not activate DCs (Fig. 1) , suggesting the methods used for the prepara tion of HMGN1 and HMGN2 can yield endotoxinfree protein preparations. Although HMGN2 has limited homol ogy (50%) with HMGN1 and is only 10 aa shorter than HMGN1, it is unclear why HMGN2 does not possess a DC activating effect. Additionally, synthetic N1ND peptide cor responding to the Nterminal domain of HMGN1 (less likely to be contaminated with endotoxin) also demonstrated a DCactivating effect (Fig. 1, E and F) . Furthermore, HMGN1 expressed in insects and purified under sterile conditions in duced DC activation in a manner that was dependent on of innate and adaptive immune responses Bianchi, 2007; Yang et al., 2009 ). HMGN1, a member of the HMGN subfamily of HMG proteins which regulates chromatin structure and gene transcription, has not previously been shown to have any extracellular activity (Bianchi and Agresti, 2005; Birger et al., 2006; Furusawa et al., 2006; Hock et al., 2007) . In this study, we show that HMGN1 is capable of activating (Figs. 1, 3 , and 4) and re cruiting (Fig. 2) human and mouse DCs, as well as promoting the development of antigenspecific Th1 polarized immune responses upon coadministration with antigens (Fig. 5) , demonstrating that extracellular HMGN1 is an authentic alarmin. The critical contribution of HMGN1 to the devel opment of antigenspecific immune responses is further sub stantiated by the fact that Hmgn1 / mice manifest much weaker antigenspecific immune responses than littermate matched Hmgn1 +/+ mice when LPS was used as the adjuvant (Fig. 6) . When antigen was administered in the form of OVAexpressing E. coli, a more physiologically relevant man ner, antigenspecific immune response in Hmgn1 / mice was still compromised (Fig. 6) . Thus, HMGN1 is an alarmin critical for the development of antigenspecific immune re sponses induced by LPS.
HMGN1 can induce DC production of various inflam matory cytokines (Figs. 1, 3 , and 4) and local recruitment of leukocytes (Fig. 2) . Preliminary data suggest that HMGN1 can also upregulate the expression of costimulatory mole cules on monocytes (not depicted). LPSinduced production of systemic (serum) and local (peritoneal lavage fluid) inflam matory cytokines as well as peritoneal infiltration of leuko cytes were greatly reduced in Hmgn1 / mice in comparison with littermatematched Hmgn1 +/+ mice (Figs. 7 and 8) . The reduction in LPSinduced innate/inflammatory response in Hmgn1 / mice is unlikely to be caused by an intrinsic defi ciency in the manifestation of inflammatory response because of HMGN1 deletion because TG and MDP induced similar peritoneal inflammatory response in both Hmgn1 +/+ and Hmgn1 / mice (Fig. 8, A and B) . Therefore, HMGN1 is also critical for the development of LPSinduced innate as well as adaptive immune responses. were injected i.p. with 0.2 ml PBS or PBS containing 10 µg/ml LPS, 5% TG, or 50 µg/ml MDP. After 24 h, peritoneal exudates were analyzed for the total cell number (A) and inflammatory mediators (IL-6, JE, and KC) in the lavage fluid (B). Shown are the results of one experiment representative of two (mean ± SD). *, P < 0.05 by ANOVA.
endogenous HMGN1 to immunity is quite unique because other endogenous TLR4 agonists did not compensate for the lack of endogenous HMGN1 in Hmgn1 / mice in promot ing the development of LPSinduced innate and antigen specific immune responses (Figs. 6, 7 , and 8). It is certain that endogenous HMGN1 is required for LPSinduced innate and adaptive immune responses; however, how endogenous HMGN1 contributes to this process is less clear. The ability of HMGN1 to bind to the TLR4 ECD -MD2 complex as judged by coimmunoprecipitation (Fig. 3 F) (Fig. 3 G) is most consistent with HMGN1 binding to a site in MD2 that is distinct from both the site in MD2 binding to LPS as well as the site engag ing TLR4 as needed to form an MD2-TLR4 heterodimer. Therefore, one possibility would be that full in vivo activa tion of TLR4 requires both endogenous HMGN1 and endo toxin. Further studies are also needed to determine whether HMGN1 is critical for the development of immune responses induced by adjuvants other than LPS.
Overall, our data demonstrate that HMGN1 acts as a critical alarmin for LPSinduced innate and antigenspecific immune responses. The findings in this study may have broader ramifications. First of all, it has been observed that aged Hmgn1 / mice have a higher incidence of multiple malignant and metastatic tumors than littermatematched Hmgn1 +/+ controls (Birger et al., 2005) . The increased spon taneous occurrence of malignant tumors in Hmgn1 / mice is thought to be based on reduced DNA repair caused by the absence of nuclear HMGN1 (Birger et al., 2005; Hock et al., 2007) . However, a reduction in antitumor immunity caused by HMGN1 deficiency may also be contributory because the activation of TLR4 is important for the generation of anti tumor immunity (Apetoh et al., 2007) . Second, one may use exogenous HMGN1 as a defined potent molecular adjuvant for promoting the efficiency of vaccines, or conversely, one can identify antagonists to target undesirable pathological in flammatory or immune reactions by suppressing the activity or release of extracellular HMGN1. Finally, HMGN1 may provide a means for nonleukocytes to respond to danger by rapidly alerting the host defense.
MATERIALS AND METHODS
Reagents and mice. Recombinant human or mouse GMCSF, IL4, IL1, TNF, soluble CD40 ligand, CXCL12, CCL5, and CCL21 were purchased from PeproTech. Con A, PHA, LPS (E. coli O55:B5), and alum were ob tained from SigmaAldrich. EndoGrade OVA with extremely low endo toxin levels (<1 EU/mg) was purchased from PROFOS. AVA was obtained from BioPort. Recombinant HMGN1, HMGN2, and mutated HMGN1 were generated in E. coli and purified as previously described (Lim et al., 2004) . The purity of the HMGN preparation was analyzed by Coomassie brilliant blue staining of an SDSPAGE. The potential endotoxin contami nation was monitored using the Chromogenic LAL Assay kit (Cambrex). Peptides corresponding to HMGN1 1-52 (N1ND) and HMGN1 53-100 (N1CD) with a purity of >95% were chemically synthesized by New England Peptide, Inc. To produce human HMGN1 in insect cells, HMGN1 cDNA was cloned into pFastBac/HBMTOPO vector (Invitrogen). To facilitate detection and purification, both cMyc and polyHis motifs were cloned inframe after TLR4, MyD88, and TRIF (Fig. 4) . These data clearly indicate that HMGN1 itself, rather than endotoxin contamination, is responsible for the observed immunoenhancing effect.
Recombinant HMGN1 produced in insects (riN1) was less active than that generated in E. coli in terms of inducing cytokine production by DCs (Figs. 1, 3, and 4) . This was probably because of the addition to riN1 of a Cterminal tag consisting of both cMyc and polyHis motifs, which were engineered for easy detection and purification of riN1. Con sequently, riN1 was 20% bigger than HMGN1 generated in E. coli, and thus a higher mass concentration was needed to achieve similar molar concentration and biological effect. In addition, the Cterminal cMyc-polyHis tag might influ ence the structure of riN1 and therefore negatively affect its potency to activate DCs.
How does HMGN1 contribute to the development of LPSinduced antigenspecific immune response? HMGN1 gene deletion does not result in deficiency in the develop ment of lymphoid organs or the reactivity and function of lymphocytes and DCs. Therefore, it is likely that HMGN1 generated at the site of immunization, in turn, promotes both the mobilization of DCs (peritoneal cavity in the present study) and the activation of innate immune response, both of which are important for the induction of subsequent adaptive immune responses. Indeed, HMGN1 is produced at the size of immunization (Fig. 7 C) . Hmgn1 / mice had greatly reduced production of serum inflammatory cytokines such as IL1, IL6, IL12, and TNF after i.p. immunization with a mixture of OVA and LPS (Fig. 7 A) . Additionally, LPS in duction of peritoneal innate/inflammatory response (leuko cyte infiltration and production of inflammatory mediators) was greatly decreased in HMGN1 KO mice (Figs. 7 and 8) . Thus, lack of endogenous HMGN1 markedly compromises LPSinduced innate/inflammatory responses. Furthermore, the reduction in antigenspecific immune responses in Hmgn1 / mice was accompanied by a lack of DC accumu lation in the peritoneum, which was intact in the peritoneum of immunized Hmgn1 +/+ mice (Fig. 7 B) . Promotion of DC activation by extracellular HMGN1 depends on the presence of MyD88 (Fig. 3 C) , which is also in agreement with the essential role of MyD88 in the induction of antigenspecific immune response (Adachi et al., 1998; Feng et al., 2003; Su et al., 2005) .
HMGN1 activates DCs by triggering a TLR4-MyD88-TRIFdependent signaling pathway, independent of its chro matinbinding capacity (Figs. 1, 3, and 4; and Figs. S1 and S2) , and thus appears to be an endogenous TLR4 agonist. Other reported endogenous TLR4 agonists include mouse defensin 2, HMGB1, heatshock proteins, granulysin, S100A8/9, and certain degraded extracellular matrix such as low molecular weight hyaluronan and fibronectin extra do main A (Ohashi et al., 2000; Okamura et al., 2001; Biragyn et al., 2002; Termeer et al., 2002; Park et al., 2004; Apetoh et al., 2007; Vogl et al., 2007; Tewary et al., 2010) . The ca pacity of TLR4 to respond to these diverse endogenous me diators remains mysterious. However, the contribution of enumerated with a hemocytometer, whereas cytokines in the lavage fluid were measured by cytokine array. The percentage of total DCs (as CD11c + / IA/E + cells) was analyzed by flow cytometry after staining total leukocytes with PEconjugated antimouse CD11c (IgG1, 2, clone HL3; BD) and FITCconjugated anti-mouse IA/E (IgG2a, , clone 2G9; BD). The sub sets of DCs recruited into the peritoneal cavity were analyzed after staining the total leukocytes with FITCconjugated anti-mouse CD11b (IgG2b, , clone M1/70; BD), PEconjugated anti-mouse CD11c, and APCconjugated anti-mouse B220 (IgG2a, , clone RA36B2; BD). The results were calcu lated as the number of cells per mouse peritoneal cavity.
Coimmunoprecipitation and Western blot. Recombinant HMGN1 was incubated with the hTLR4-MD2 complex (R&D Systems) in PBS at a concentration of 10 µM for 30 min at room temperature. The mixture was then mixed with Dynabeads (Invitrogen) that were precoated with rabbit antiHMGN1 IgG, mouse antihMD2 IgG, normal rabbit IgG, or normal mouse IgG and incubated at room temperature for 20 min. Subsequently, the Dynabeads were separated from the free reactants with a magnet and washed three times with wash buffer as recommended by the manufacturer. Finally, the Dynabeads were suspended in 18 µl of 1× SDSPAGE sample buffer (62.5 mM TrisHCl, pH 6.8 at 25°C, 2% wt/vol SDS, 10% glycerol, 50 mM dithiothreitol, and 0.01% bromophenol blue) and boiled for 5 min, and the supernatants were collected for SDSPAGE separation and Western blot analysis.
DCs with HMGN1 as specified and leukocytes recovered from the peritoneal lavage of treated mice were washed and lysed in SDSPAGE sam ple buffer at 10 7 /ml. Protein pellets of trichloroacetic acid-precipitated supernatant (3 ml) of peritoneal lavage were dissolved in 20 µl SDSPAGE sample buffer. Samples (10-20 µl/lane) were separated on a 4-12% NuPAGE BisTris Gel using 1× NuPAGE MES SDS Running buffer as the elec trode buffer. After transfer onto a piece of Immobilon membrane (Millipore), the levels of target molecules were detected by blotting using the following first antibody: mouse antipolyhistidine, rabbit antiHMGN1 (ProteinTech), rabbit anti-IB (Cell Signaling Technology), rabbit antiGAPDH (Cell Signaling Technology), rabbit anti-phosphop44/42 (Cell Signaling Tech nology), antip44/42 (Cell Signaling Technology), rabbit anti-phosphory lated p38 (Cell Signaling Technology), rabbit antip38 (Cell Signaling Technology), rabbit anti-phosphorylated JNK (Cell Signaling Technology), and rabbit antiJNK (Cell Signaling Technology). Horseradish peroxidaseconjugated anti-mouse IgG (GE Healthcare) or anti-rabbit IgG (Cell Signal ing Technology) was used as the second antibody. The blot was developed using the ECL Plus Western Blotting Detection System (GE Healthcare) and exposed to a piece of BioMax xray film (Kodak).
Assay of HMGN1 binding to the TLR4-MD2 complex. [ 3 H]LOS
with a specific radioactivity of 25,000 cpm/pmol was prepared as previously described (Giardina et al., 2001) . The preparation of FLAG-TLR4 ECD , TLR4 ECD -MD2, [ 3 H]LOS-MD2, and [ 3 H]LOS-CD14 and the binding analysis were performed as previously reported (Teghanemt et al., 2008; Piazza et al., 2011) . In brief, 0.5 nM FLAG-TLR4 ECD -MD2 was incubated with 0. (1,200, V i ). The reaction mixture was applied to the Sephacryl HR S300 column pre equilibrated in PBS, pH 7.4, and 0.1% HSA and eluted in the same buffer HMGN1 cDNA so that the HMGN1 would be expressed as a protein with a Cterminal cMyc-polyHis tag. After sequence confirmation, the construct was transformed into Max Efficiency DH10Bac competent E. coli (Invitrogen) to generate recombinant bacmid. The bacmid was transfected into Sf9 insect cells (Invitrogen) to make recombinant baculovirus. The 48h culture super natant of High Five cells infected by the recombinant baculovirus (at a multi plicity of infection of 10) was used for the purification of secreted HMGN1 (termed riN1) by affinity chromatography under sterile condition using nickel affinity columns. C57BL/6 and A/J mice were obtained from Charles River. OT I and OT II mice were purchased from the Jackson Laboratory. Hmgn1 / and littermatematched Hmgn1 +/+ mice were generated by genotyping the offspring of breeders consisting of Hmgn1 +/ dam and sire. MyD88 +/+ and MyD88 / mice were generated by breeding MyD88 +/ dams and sires. TRIF +/+ and TRIF / mice were generated by breeding TRIF +/ dams and sires. All mice were kept under specific pathogen-free conditions with water and food given ad libitum. All experiments with mice were performed in compliance with the principles and procedures outlined in the National Insti tutes of Health Guide for the Care and Use of Animals and were approved by the National Cancer Institute at Frederick Animal Care and Use Committee.
DC generation and treatment.
Human peripheral blood monocytes and T lymphocytes were isolated 90-95% pure as previously described (Yang et al., 2008) . Human DCs were generated by culturing purified monocytes at 5 × 10 5 /ml in complete RPMI 1640 medium (RPMI 1640 supplemented with 10% FBS [Hyclone], 2 mM glutamine, 25 mM Hepes, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM of 2ME) containing 50 ng/ml hGM CSF and 50 ng/ml hIL4 at 37°C in a humidified CO 2 (5%) incubator for 5-6 d. Mouse DCs were generated by culturing mouse hematopoietic progenitors isolated from the femurs and tibias of various KO and littermatematched WT mice in complete RPMI 1640 containing 20 ng/ml mGMCSF for 6 d as previously reported (Yang et al., 2008) . Human and mouse DCs were incu bated at specified concentrations for 20 min to 48 h in the absence or presence of the indicated concentration of activators (e.g., HMGN1, LPS, etc.) before being analyzed for phenotype, function, or signaling. In some experiments, mouse DCs were pulsed with antigen by incubating with 100 µg/ml OVA for 24 h before induction of maturation.
Assessment of DC phenotype and function. Multiple cytokines and che mokines in the culture supernatants of human and mouse DCs were measured using SearchLight cytokine array (Thermo Fisher Scientific). DC migration was assessed using a 48well microchemotaxis chamber assay as described pre viously (Kurosaka et al., 2005) . Expression of surface molecules on human DCs was determined by flow cytometry using a FACScan (BD) after staining with FITC or PEconjugated mouse monoclonal antibodies (all from BD) against human CD11c (IgG1, , clone BLy6), CD80 (IgG1, , clone L307.4), CD83 (IgG1, , clone HB15e), CD86 (IgG1, , clone 2331), HLAABC (IgG1, , clone G462.6), HLADR (IgG2a, , clone G466), or isotype matched control antibodies. The capacity of DCs to stimulate the proliferation of allogeneic T cells was evaluated by mixed lymphocyte reaction in which purified allogeneic T cells or OT I/II lymphocytes (10 5 /well) were cultured with different numbers of differentially treated and irradiated (3,000 rad) DCs in a 96well flatbottom plate for a specified period of time at 37°C in humidified air with 5% CO 2 . The proliferative response of T cells was exam ined by pulsing the culture with 1 µCi/well [ 3 H]TdR (DuPont) for the last 18 h before harvest. [ 3 H]TdR incorporation was measured with a microbeta counter (Wallac).
Analysis of in vivo cell recruitment and HMGN1 production. Male or female mice (C57BL/6, Hmgn1 +/+ , and Hmgn1 / ) of 8-12 wk old were injected i.p. with HMGN1, OVA, TG, MDP, and LPS alone or in combination at specified doses. After 4-22 h, the mouse peritoneal cavity was lavaged with 5 ml of icecold Ca 2+ and Mg 2+ free PBS containing 20 U/ml heparin. The lavage fluid was centrifuged (300 g) for 5 min to separate the supernatant and cells. HMGN1 in the supernatant or cells was detected by Western blot as described in the following section. Total leukocytes were Generation of bone marrow chimeric mice. For the generation of WT→KO chimeric mice, lethally irradiated (1,000 rad) HMGN1 KO (Hmgn1 / ) mice (8 wk old) were reconstituted by intravenous injection of bone marrow mononuclear cells (5 × 10 6 /mouse) isolated from sex and littermatematched WT (Hmgn1 +/+ ) mice. For the generation of KO→WT chimeric mice, Hmgn1 / bone marrow mononuclear cells were injected into Hmgn1 +/+ mice. After reconstitution, mice were housed under specific pathogen-free conditions with amoxicillin in the drinking water for 8 wk to allow the development of chimeric mice before use.
Immunization and detection of antigen-specific immune responses. C57BL/6, Hmgn1 / or littermatematched Hmgn1 +/+ , A/J, or chimeric mice (8-15 wk old, male or female, three to six mice/group) were immu nized i.p. with PBS, antigen (OVA or AVA) alone or in the presence of alum (2-3 mg/mouse), HMGN1 (1-5 µg/mouse), or LPS (1 µg/mouse) on day 1 or irradiationinactivated EC OVA and i.p. booster immunized on day 14. Serum samples were taken on day 10 and 20 for the measurement of pri mary and secondary antibody responses. In some experiments, serum was taken at 24 and 96 h after immunization for the detection of in vivo cytokine generation. On day 21, immunized mice were euthanized to remove spleens for the measurement of antigenspecific splenocyte proliferation and cyto kine production. OVAspecific IgG antibody was measured by ELISA as previously described (Yang et al., 2008) . The titer of IgG specific for the PA of anthrax toxin in the serum of AVAimmunized A/J mice was quantitated by antiPA ELISA as previously reported (Xie et al., 2005) .
OVAspecific splenocyte proliferation was measured by incubating splenocytes (5 × 10 5 /well) in triplicate in wells of 96well roundbottomed plates in complete RPMI 1640 medium (0.2 ml/well) in the presence or ab sence of the indicated concentration of OVA at 37°C in a CO 2 incubator for 72 h. The cultures were pulsed with 1 µCi/well for the last 18 h before har vest for the quantitation of [ 3 H]TdR incorporation by microbeta counting. For measuring OVAspecific cytokine production, splenocytes were cul tured in complete RPMI 1640 in 48well plates (2.5 × 10 6 /0.5 ml/well) with the indicated concentrations of OVA for 48 h. Cytokines produced by splenocytes in the culture supernatants were quantitated by SearchLight cytokine array (Thermo Fisher Scientific).
Statistical analysis. Unless otherwise specified, all experiments were per formed at least three times, and the results of one representative experiment or the mean of multiple experiments are shown. Differences in the produc tion of antigenspecific IgG and cytokines of treated mice were determined by analysis of variance (ANOVA), whereas differences between other sham and experimentally treated groups were evaluated by Student's t test.
Online supplemental material. Fig. S1 shows that mutated HMGN1 incapable of chromatin binding was similarly effective at upregulating the expression of DC surface marker molecules. Fig. S2 shows that HMGN1 induction of cytokines depends on the TLR4-MD2 signaling complex. Fig. S3 shows the preparation and purity of recombinant HMGN1 pro tein. Fig. S4 shows that the capacity of HMGN1 to induce DC production of IL6 and TNF was destroyed by heating but not by DNase I digestion. Fig. S5 shows that the splenocytes of immunized WT and HMGN1 KO mice proliferated similarly in response to various polyclonal stimulators. Fig. S6 shows that Hmgn1 / and littermatematched Hmgn1 +/+ mice have similar distribution of various subsets of leukocytes. Fig. S7 shows that DCs of Hmgn1 / and littermatematched Hmgn1 +/+ mice had compa rable antigenuptake and antigenpresenting capacity as well as signaling. Fig. S8 shows OVAspecific splenocyte proliferation of immunized chimeric mice. Online supplemental material is available at http://www.jem.org/cgi/ content/full/jem.20101354/DC1.
